MEF2C Alleviates Postoperative Cognitive Dysfunction by Repressing Ferroptosis
View abstract on PubMed
Summary
This summary is machine-generated.Myocyte-specific enhancer factor 2C (MEF2C) protects against postoperative cognitive dysfunction (POCD) by inhibiting ferroptosis. MEF2C overexpression improved memory and reduced cell damage, suggesting it as a therapeutic target for POCD.
Area Of Science
- Neuroscience
- Cell Biology
- Genetics
Background
- Postoperative cognitive dysfunction (POCD) is linked to ferroptosis, a cell death pathway involving lipid peroxidation.
- Myocyte-specific enhancer factor 2C (MEF2C), a transcription factor, is involved in cognitive processes and brain function.
- The role of MEF2C in POCD and its connection to ferroptosis remain unclear.
Purpose Of The Study
- To investigate whether MEF2C influences cognitive function after surgery by modulating ferroptosis.
- To explore the therapeutic potential of targeting MEF2C for preventing POCD.
Main Methods
- Transcriptomic analysis identified MEF2C as differentially expressed in POCD mouse hippocampus.
- A POCD mouse model was created using anesthesia and surgery, with manipulated MEF2C and GPX4 inhibitor (RSL3) levels.
- Cognitive function, cell damage markers, ferroptosis indicators, and MEF2C's transcriptional regulation of GPX4 were assessed.
Main Results
- MEF2C levels decreased in the hippocampus post-surgery and anesthesia.
- Overexpressing MEF2C improved memory, reduced lipid peroxidation and iron accumulation, and boosted antioxidant capacity.
- MEF2C directly activated GPX4 transcription by binding to its promoter, an effect reversed by RSL3.
Conclusions
- MEF2C plays a protective role against POCD by suppressing ferroptosis.
- MEF2C's ability to transcriptionally activate GPX4 is key to its neuroprotective effects.
- MEF2C represents a potential therapeutic target for mitigating POCD.

